Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiellapneumoniae carbapenemase- producing K pneumoniae: A case report and review of literature

Open Forum Infectious Diseases

Volumn 4, Issue 3, 2017, Pages 1-4

  Shields, Ryan K ^a,b   Nguyen, M Hong ^a,b   Press, Ellen G ^a   Chen, Liang ^c   Kreiswirth, Barry N ^c   Clancy, Cornelius J ^a,b,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Carbapenem resistant Enterobacteriaceae; Ceftazidime avibactam resistance; Klebsiella pneumoniae carbapenemase; KPC mutations; Sequence type 258 Klebsiella pneumoniae

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; CARBAPENEM; CARBAPENEMASE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; MEROPENEM;

ABDOMINAL ABSCESS; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE CLEARANCE; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; HUMAN; KIDNEY INJURY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LEUKOCYTOSIS; LOG CELL KILL; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY FAILURE; VENTILATOR ASSOCIATED PNEUMONIA; WHOLE GENOME SEQUENCING;

EID: 85023598095     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofx101     Document Type: Article

References (10)

1. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 26th ed. M100S. Wayne, PA. 2017.
2. KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 2017; 61:pii: e02097-16.
3. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005; 49:1337-9.
4. Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016; 63: 1615-8.
5. Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 2017; 61:pii: e01964-16.
6. Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014; 20:862-72.
7. KPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2017; 61:pii: e02534-16.
8. Livermore DM, Warner M, Jamrozy D, et al. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 2015; 59:5324-30.
9. Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop. J Antimicrob Chemother 2015; 70:2279-86.
10. Shields RK, Nguyen MH, Press EG, et al. In vitro selection of meropenem resistance among ceftazidime-avibactam resistant, meropenem susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases. Antimicrob Agents Chemother 2017; 61:pii: e.00079-17.